133 related articles for article (PubMed ID: 38334801)
1. Sintilimab-induced autoimmune diabetes mellitus manifesting as diabetic ketoacidosis in a patient with advanced esophageal squamous cell carcinoma.
Lai N; Fan X; Liu S
Acta Diabetol; 2024 May; 61(5):675-678. PubMed ID: 38334801
[No Abstract] [Full Text] [Related]
2. Diabetic ketoacidosis following immunotherapy for lung cancer.
Skorpen PK; Margull J
Tidsskr Nor Laegeforen; 2019 Feb; 139(4):. PubMed ID: 30808100
[No Abstract] [Full Text] [Related]
3. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
Huang X; Yang M; Wang L; Li L; Zhong X
Medicine (Baltimore); 2021 May; 100(19):e25795. PubMed ID: 34106616
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Xu J; Li Y; Fan Q; Shu Y; Yang L; Cui T; Gu K; Tao M; Wang X; Cui C; Xu N; Xiao J; Gao Q; Liu Y; Zhang T; Bai Y; Li W; Zhang Y; Dai G; Ma D; Zhang J; Bai C; Huang Y; Liao W; Wu L; Chen X; Yang Y; Wang J; Ji S; Zhou H; Wang Y; Ma Z; Wang Y; Peng B; Sun J; Mancao C
Nat Commun; 2022 Feb; 13(1):857. PubMed ID: 35165274
[TBL] [Abstract][Full Text] [Related]
5. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
[TBL] [Abstract][Full Text] [Related]
6. Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report.
Fu L; Chen P; Wang S; Liu W; Chen Z; Chen H; Fu Z
Anticancer Drugs; 2022 Jan; 33(1):e741-e746. PubMed ID: 34338239
[TBL] [Abstract][Full Text] [Related]
7. Sintilimab-Induced Diabetic Ketoacidosis in a Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review.
Lv C; Wu C; Zhang Y; Li W; Wang X; Liang L
Curr Oncol; 2022 Oct; 29(11):7987-7993. PubMed ID: 36354692
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: A long-awaited breakthrough finally arrives.
Kuo HY; Guo JC; Hsu CH
J Formos Med Assoc; 2020 Feb; 119(2):565-568. PubMed ID: 31668650
[No Abstract] [Full Text] [Related]
9. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z; Wang J; Shu Y; Liu L; Kong L; Yang L; Wang B; Sun G; Ji Y; Cao G; Liu H; Cui T; Li N; Qiu W; Li G; Hou X; Luo H; Xue L; Zhang Y; Yue W; Liu Z; Wang X; Gao S; Pan Y; Galais MP; Zaanan A; Ma Z; Li H; Wang Y; Shen L;
BMJ; 2022 Apr; 377():e068714. PubMed ID: 35440464
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.
Qiu HB
Thorac Cancer; 2020 Dec; 11(12):3419-3421. PubMed ID: 33043992
[No Abstract] [Full Text] [Related]
11. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
Hong AR; Yoon JH; Kim HK; Kang HC
Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
[TBL] [Abstract][Full Text] [Related]
14. Diabetic ketoacidosis as a hallmark of autoimmune diabetes occurring after two cycles of cemiplimab.
Jouneghani NS; Phillip J; Dasanu CA
J Oncol Pharm Pract; 2022 Apr; 28(3):722-724. PubMed ID: 34791931
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.
Shah MA; Kojima T; Hochhauser D; Enzinger P; Raimbourg J; Hollebecque A; Lordick F; Kim SB; Tajika M; Kim HT; Lockhart AC; Arkenau HT; El-Hajbi F; Gupta M; Pfeiffer P; Liu Q; Lunceford J; Kang SP; Bhagia P; Kato K
JAMA Oncol; 2019 Apr; 5(4):546-550. PubMed ID: 30570649
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare data.
Danese M; Gricar J; Abraham P
Future Oncol; 2022 Mar; 18(8):927-936. PubMed ID: 35081734
[TBL] [Abstract][Full Text] [Related]
17. Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.
Yan Z; Yao ZH; Yao SN; Wang HY; Chu JF; Song M; Zhao S; Liu YY
Immunotherapy; 2020 Nov; 12(16):1161-1166. PubMed ID: 32814482
[No Abstract] [Full Text] [Related]
18. Atezolizumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis and Takotsubo cardiomyopathy.
Singhal S; Patel G; Singh RB; Goyal A; Avgush K; Koka J
BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35793858
[TBL] [Abstract][Full Text] [Related]
19. Toripalimab and chemotherapy in oesophageal squamous cell carcinoma.
Hindson J
Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):280. PubMed ID: 35396542
[No Abstract] [Full Text] [Related]
20. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Kojima T; Shah MA; Muro K; Francois E; Adenis A; Hsu CH; Doi T; Moriwaki T; Kim SB; Lee SH; Bennouna J; Kato K; Shen L; Enzinger P; Qin SK; Ferreira P; Chen J; Girotto G; de la Fouchardiere C; Senellart H; Al-Rajabi R; Lordick F; Wang R; Suryawanshi S; Bhagia P; Kang SP; Metges JP;
J Clin Oncol; 2020 Dec; 38(35):4138-4148. PubMed ID: 33026938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
